Apellis Pharmaceuticals Inc (NASDAQ: APLS) kicked off on Friday, down -11.32% from the previous trading day, before settling in for the closing price of $22.52. Over the past 52 weeks, APLS has traded in a range of $21.70-$58.12.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 92.54% over the last five years. While this was happening, its average annual earnings per share was recorded 38.37%. With a float of $104.48 million, this company’s outstanding shares have now reached $124.50 million.
The firm has a total of 710 workers. Let’s measure their productivity. In terms of profitability, gross margin is 84.82%, operating margin of -21.11%, and the pretax margin is -25.18%.
Apellis Pharmaceuticals Inc (APLS) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Apellis Pharmaceuticals Inc is 16.76%, while institutional ownership is 99.36%. The most recent insider transaction that took place on Mar 17 ’25, was worth 4,543. In this transaction VP/Chief Accounting Officer of this company sold 183 shares at a rate of $24.82, taking the stock ownership to the 47,955 shares. Before that another transaction happened on Mar 17 ’25, when Company’s Officer proposed sale 183 for $24.82, making the entire transaction worth $4,543.
Apellis Pharmaceuticals Inc (APLS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 38.37% per share during the next fiscal year.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Take a look at Apellis Pharmaceuticals Inc’s (APLS) current performance indicators. Last quarter, stock had a quick ratio of 3.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.60, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach 0.17 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
Analysing the last 5-days average volume posted by the [Apellis Pharmaceuticals Inc, APLS], we can find that recorded value of 3.29 million was better than the volume posted last year of 1.92 million. As of the previous 9 days, the stock’s Stochastic %D was 23.66%. Additionally, its Average True Range was 1.37.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 1.35%, which indicates a significant decrease from 3.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.84% in the past 14 days, which was higher than the 59.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.27, while its 200-day Moving Average is $31.79. Now, the first resistance to watch is $22.13. This is followed by the second major resistance level at $24.29. The third major resistance level sits at $25.47. If the price goes on to break the first support level at $18.78, it is likely to go to the next support level at $17.60. Should the price break the second support level, the third support level stands at $15.44.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
The company with the Market Capitalisation of 2.51 billion has total of 125,516K Shares Outstanding. Its annual sales at the moment are 781,370 K in contrast with the sum of -197,880 K annual income. Company’s last quarter sales were recorded 212,530 K and last quarter income was -36,350 K.
